Strides Pharma Science · NSE: STAR · BSE: 532531

Q3 FY20 results · Oct–Dec 2019

Strides Pharma Science reported revenue from operations of ₹732.44 crore (down 7.8% from Q3 FY19) and net profit of ₹92.33 crore (down 68.9% from Q3 FY19) for Q3 FY20 (Oct–Dec 2019), on a consolidated basis.

Consolidated · ₹ crore
Item	Q3 FY20	Q3 FY19	YoY	Q2 FY20	QoQ
Revenue from operations	732.44	794.50	−7.8%	715.09	+2.4%
Other income	12.22	0.83	15x	12.99	−5.9%
Total income	744.66	795.33	−6.4%	728.08	+2.3%
Profit before share of associates & JVs and tax	127.02	37.90	+235.1%	161.68	−21.4%
Share of profit/(loss) of associates & JVs	(23.39)	(6.96)		(21.25)
Net profit for the period	92.33	296.43	−68.9%	141.91	−34.9%
Attributable to shareholders of the company	93.89	293.42	−68.0%	142.72	−34.2%
EPS, basic (₹)	10.48	32.77	−68.0%	15.94	−34.3%
Net margin (%)	12.6	37.3		19.8

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q3 FY20	Q3 FY19	YoY	Q2 FY20	QoQ
Revenue from operations	364.47	414.68	−12.1%	425.41	−14.3%
Other income	17.62	22.07	−20.2%	32.20	−45.3%
Total income	382.09	436.75	−12.5%	457.61	−16.5%
Profit before tax	15.53	17.80	−12.8%	58.22	−73.3%
Net profit for the period	13.65	15.31	−10.8%	47.00	−71.0%
EPS, basic (₹)	1.52	1.71	−11.1%	5.25	−71.0%
Net margin (%)	3.7	3.7		11.0

Consolidated

Filed with BSE: 30 Jan 2020, 13:17 IST
Board meeting: 30 Jan 2020
Period: 01 Oct 2019 to 31 Dec 2019
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 30 Jan 2020, 13:17 IST
Board meeting: 30 Jan 2020
Period: 01 Oct 2019 to 31 Dec 2019
Review status: Unaudited
Source: XBRL filing on BSE